Allopurinol

Generic Name
Allopurinol
Brand Names
Aloprim, Zyloprim
Drug Type
Small Molecule
Chemical Formula
C5H4N4O
CAS Number
315-30-0
Unique Ingredient Identifier
63CZ7GJN5I
Background

Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...

Indication

Allopurinol is indicated in :

1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...

Associated Conditions
Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
Associated Therapies
-
Clinical Trials
Related News

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Phase 3
Completed
Conditions
Gout
Interventions
Drug: Febuxostat
Drug: Allopurinol
First Posted Date
2005-01-31
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
760
Registration Number
NCT00102440

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

First Posted Date
2004-05-20
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
163
Registration Number
NCT00003700
Locations
🇺🇸

University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 47 locations

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
Interventions
Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2003-06-06
Last Posted Date
2022-05-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
302
Registration Number
NCT00061945
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

First Posted Date
2003-01-28
Last Posted Date
2016-07-01
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
82
Registration Number
NCT00053196
Locations
🇺🇸

Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States

🇺🇸

Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States

and more 9 locations

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

First Posted Date
2003-01-27
Last Posted Date
2023-08-21
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
105
Registration Number
NCT00039130
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 28 locations

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
HIV Infections
Lymphoma, Non-Hodgkin
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
250
Registration Number
NCT00000658
Locations
🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

🇺🇸

USC CRS, Los Angeles, California, United States

🇺🇸

Ucsf Aids Crs, San Francisco, California, United States

and more 19 locations

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Not Applicable
Completed
Conditions
Lymphoma, Non-Hodgkin
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
45
Registration Number
NCT00000703
Locations
🇺🇸

Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States

🇺🇸

Julio Arroyo, West Columbia, South Carolina, United States

🇺🇸

Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States

and more 11 locations

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil

Phase 2
Completed
Conditions
Leishmaniasis
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
375
Registration Number
NCT00004755
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy